HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

AVTX

Avalo Therapeutics Inc

Last Close
18.42
Jul 14 • 03:59PM ET Dollar change-0.49 Percentage change(-2.59%)
Aftermarket Close
18.42
Aftermarket • 05:00PM ET Dollar change0.00 Percentage change(0.00%)
Overview Compare Short Interest Financials Options Filings
Healthcare Biotechnology USA Small NASD
Peers: KYMR NUVL RYTM INCY BMRN VKTX KRYS AXSM MDGL NBIX
 | Held by: XBI VTI IWM VXF IWO IWN IWC FESM ITOT LABU
Scroll to Statements
Index
RUT
Market Cap
968.25M
Enterprise Value
888.44M
Income
-84.74M
Sales
0.06M
Book/sh
2.77
Cash/sh
1.56
Dividend Est.
0.01 (0.06%)
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
33
IPO
Nov 13, 2015
P/E
-
Forward P/E
-
PEG
-
P/S
16137.55
P/B
6.64
P/C
11.79
P/FCF
-
EV/EBITDA
-
EV/Sales
14807.38
Quick Ratio
7.66
Current Ratio
7.66
Debt/Eq
0.03
LT Debt/Eq
0.03
Option/Short
Yes / Yes
EPS (ttm)
-5.82
EPS next Y
-2.99
EPS next Q
-0.58
EPS this Y
48.80%
EPS next Y
0.00%
EPS next 5Y
22.98%
EPS past 3/5Y
82.35% 70.20%
Sales past 3/5Y
-85.16% -61.19%
EPS Y/Y TTM
-1121.44%
Sales Y/Y TTM
-86.62%
EPS Q/Q
21.93%
Sales Q/Q
-
Earnings
May 13 BMO
EPS/Sales Surpr.
4.42% -
Insider Own
8.98%
Insider Trans
-6.35%
Inst Own
75.11%
Inst Trans
21.73%
ROA
-71.09%
ROE
-88.76%
ROIC
-120.51%
Gross Margin
-283.05%
Oper. Margin
-134164.41%
Profit Margin
-143627.12%
SMA20
3.16%
SMA50
8.76%
SMA200
13.94%
Trades
Shs Outstand
52.57M
Shs Float
47.84M
Short Float
25.73%
Short Ratio
6.25
Short Interest
12.31M
52W High
24.27 -24.10%
52W Low
4.72 290.01%
Volatility
6.57% 7.68%
ATR (14)
1.31
RSI (14)
54.47
Beta
0.81
Rel Volume
0.43
Avg Volume
1.97M
Volume
850,695
Perf Week
-4.31%
Perf Month
34.75%
Perf Quarter
38.08%
Perf Half Y
8.67%
Perf YTD
1.43%
Perf Year
275.92%
Perf 3Y
-76.89%
Perf 5Y
-99.79%
Perf 10Y
-99.73%
Recom
1.00
Target Price
44.69
Prev Close
18.91
Price
18.42
Change
-2.59%
Date Action Analyst Rating Change Price Target Change
Jul-06-26Initiated Leerink Partners Outperform $38
Jun-12-26Initiated BofA Securities Buy $35
Apr-09-26Initiated Wolfe Research Outperform $48
Apr-06-26Initiated Citizens Mkt Outperform $52
Feb-02-26Initiated Guggenheim Buy $50
Dec-18-25Initiated Mizuho Outperform $39
Sep-17-25Reiterated H.C. Wainwright Buy $15 → $25
Sep-05-25Initiated TD Cowen Buy
Aug-15-25Initiated Cantor Fitzgerald Overweight
Jun-02-25Resumed H.C. Wainwright Buy $15
Show Previous Ratings
Jul-07-26 07:00AM
Avalo Therapeutics to Participate in the Leerink Partners Therapeutics Forum
(GlobeNewswire)
Jun-26-26 07:00AM
Avalo Therapeutics to Join the Russell 2000 and Russell 3000 Indexes
(GlobeNewswire)
Jun-23-26 07:00AM
Avalo Therapeutics Appoints Ron Philip to Board of Directors
(GlobeNewswire)
Jun-16-26 07:00AM
Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1ß Antibody
(GlobeNewswire)
May-22-26 04:01PM
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire)
07:00AM Loading…
May-13-26 07:00AM
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
(GlobeNewswire)
May-06-26 06:30AM
Avalo shares spike on skin drug data; BioNTech to cut staff
(BioPharma Dive) +34.13%
May-05-26 11:33PM
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
(GlobeNewswire) +18.00%
04:05PM
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
(GlobeNewswire)
04:01PM
Avalo Therapeutics Achieves Positive Topline Results in Phase 2 LOTUS Trial of Abdakibart (AVTX-009) in Moderate to Severe Hidradenitis Suppurativa
(GlobeNewswire)
Apr-28-26 07:00AM
Avalo Therapeutics Purchases Optional Milestone Buyout
(GlobeNewswire) -10.82%
Apr-03-26 08:00PM
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
(Quartz)
Mar-23-26 07:00AM
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
(GlobeNewswire)
Mar-05-26 07:07AM
Avalo Therapeutics Highlights AVTX-009 Plan, Near-Term Phase II HS Data at Healthcare Conference
(MarketBeat)
Feb-25-26 08:06PM
Avalo Therapeutics Highlights AVTX-009 HS Phase II Catalyst, Cash Runway at Oppenheimer Conference
(MarketBeat)
07:00AM Loading…
Feb-24-26 07:00AM
Avalo Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire) +9.46%
Feb-18-26 04:05PM
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +6.47%
Feb-11-26 06:39PM
Avalo Therapeutics Eyes Q2 2026 Phase IIb LOTUS Readout for AVTX-009 in Hidradenitis Suppurativa
(MarketBeat)
Feb-04-26 07:00AM
Avalo Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire) -9.96%
Feb-02-26 02:25PM
Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case
(Benzinga)
Nov-17-25 04:30PM
Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
(GlobeNewswire) +11.68% +6.67%
Nov-06-25 07:00AM
Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates
(GlobeNewswire) -6.26%
Nov-03-25 07:00AM
Avalo Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire) -7.54%
Oct-29-25 11:57AM
Piper Sandler Maintains Bullish $48 Price Target on Avalo Therapeutics (AVTX)
(Insider Monkey)
07:00AM
Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
(GlobeNewswire)
Oct-01-25 07:00AM
Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources
(GlobeNewswire)
Sep-22-25 07:00AM
Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors
(GlobeNewswire)
Aug-27-25 07:00AM
Avalo Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Aug-15-25 09:32AM
Target downgraded, Salesforce upgraded: Wall Street's top analyst calls
(The Fly)
Aug-07-25 07:00AM
Avalo Reports Second Quarter 2025 Financial Results and Recent Business Updates
(GlobeNewswire)
10:03PM Loading…
Jul-02-25 10:03PM
Avalo Adds Dr. Rita Jain to Board as LOTUS Trial Advances
(Insider Monkey)
Jun-23-25 07:00AM
Avalo Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Jun-18-25 07:00AM
Avalo Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
(GlobeNewswire) +6.49%
May-27-25 10:05AM
Avalo Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
May-12-25 07:00AM
Avalo Reports First Quarter 2025 Financial Results and Recent Business Updates
(GlobeNewswire)
Apr-30-25 07:00AM
Avalo Therapeutics to Participate in The Citizens Life Sciences Conference
(GlobeNewswire)
Mar-26-25 07:00AM
Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board
(GlobeNewswire)
Mar-20-25 07:00AM
Avalo Reports 2024 Financial Results and Recent Business Updates
(GlobeNewswire)
Feb-24-25 07:00AM
Avalo Therapeutics to Participate in Upcoming Investor Conferences
(GlobeNewswire)
Feb-04-25 08:00AM
Avalo Therapeutics to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference
(GlobeNewswire)
Jan-02-25 07:00AM
Avalo Therapeutics Appoints Jennifer Riley as Chief Strategy Officer
(GlobeNewswire) +13.46%
Dec-20-24 06:50AM
Avalo Therapeutics initiated with a Buy at BTIG
(TipRanks)
Nov-12-24 07:00AM
Avalo Therapeutics Receives $69.4 Million in Proceeds from the Full Exercise of Private Placement Warrants
(GlobeNewswire)
Nov-11-24 07:00AM
Avalo Therapeutics to Present at Upcoming Investor Conferences
(GlobeNewswire)
Nov-07-24 07:00AM
Avalo Reports Third Quarter 2024 Financial Results and Recent Business Updates
(GlobeNewswire)
Nov-04-24 07:30AM
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
(PR Newswire)
Oct-08-24 07:00AM
Avalo Announces First Patient Dosed in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa
(GlobeNewswire)
Sep-04-24 07:00AM
Avalo Announces Participation in September Investor Conferences
(GlobeNewswire)
Aug-12-24 07:00AM
Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire) -7.30%
Jul-16-24 07:00AM
Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
(GlobeNewswire)
Jul-09-24 07:00AM
Avalo Therapeutics Announces Active IND for AVTX-009, an anti-IL-1ß mAb, to Treat Hidradenitis Suppurativa
(GlobeNewswire)
Jun-24-24 04:01PM
Avalo Therapeutics Announces Appointment of Paul Varki as Chief Legal Officer
(GlobeNewswire)
Jun-17-24 07:30AM
Avalo to Present at the Oppenheimer Novel Targets in Immunology Summit
(GlobeNewswire)
Jun-13-24 09:00AM
The Lustgarten Foundation Appoints Two New Board Members
(PR Newswire)
May-24-24 01:52PM
AVTX Stock Earnings: Avalo Therapeutics Misses EPS, Beats Revenue for Q4 2023
(InvestorPlace) +17.49%
May-22-24 09:40AM
Is Avalo Therapeutics (AVTX) Stock Outpacing Its Medical Peers This Year?
(Zacks)
May-13-24 03:52PM
AVTX Stock Earnings: Avalo Therapeutics Misses EPS for Q1 2024
(InvestorPlace)
07:30AM
Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
(GlobeNewswire)
Apr-02-24 11:30AM
Avalo Therapeutics (AVTX) Surges 270% in a Week: Here's Why
(Zacks) -15.31%
07:00AM
Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
(GlobeNewswire)
Mar-29-24 04:01PM
Avalo Reports 2023 Financial Results and Provides Business Updates
(GlobeNewswire)
Mar-28-24 08:04AM
Why Is Avalo Therapeutics (AVTX) Stock Up 326% Today?
(InvestorPlace) +357.89%
Mar-27-24 04:01PM
Avalo Acquires Anti-IL-1 mAb and Announces Private Placement Financing of up to $185 Million
(GlobeNewswire)
10:00AM
Will Avalo Therapeutics, Inc. (AVTX) Report Negative Q4 Earnings? What You Should Know
(Zacks)
Feb-26-24 11:28AM
Avalo (AVTX) to Report Q4 Earnings: What's in the Cards?
(Zacks)
Dec-27-23 07:00AM
Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
(GlobeNewswire)
Dec-07-23 07:00AM
Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
(GlobeNewswire) -5.61%
Nov-09-23 07:00AM
Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
(GlobeNewswire) -10.09%
Oct-31-23 07:00AM
Avalo Completes Divestiture of AVTX-800 Series
(GlobeNewswire) +18.00%
Sep-27-23 08:00AM
BestGrowthStocks.com Issues a Comprehensive Analysis of Avalo Therapeutics
(News Direct) +12.19%
Sep-26-23 07:00AM
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
(GlobeNewswire) -7.36%
Sep-12-23 07:00AM
Avalo Enters into Agreement to Divest AVTX-800 Series
(GlobeNewswire) +45.47%
Sep-06-23 07:00AM
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
(GlobeNewswire)
Aug-03-23 07:00AM
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
(GlobeNewswire)
Jul-06-23 04:01PM
Avalo to Participate in SVB Securities Therapeutics Forum
(GlobeNewswire)
Jun-26-23 07:00AM
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
(GlobeNewswire) -88.69%
Jun-01-23 07:00AM
Avalo to Present at the Jefferies Healthcare Conference
(GlobeNewswire)
May-22-23 07:00AM
Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
(GlobeNewswire) -11.76%
May-15-23 07:00AM
Avalo to Present at ATS 2023 Respiratory Innovation Summit
(GlobeNewswire) +11.79%
May-10-23 07:00AM
Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
(GlobeNewswire)
May-04-23 04:01PM
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
(GlobeNewswire) -5.37% -7.80%
Mar-29-23 07:30AM
Avalo Reports 2022 Financial Results and Provides Business Updates
(GlobeNewswire) -7.47%
Mar-07-23 07:00AM
Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference
(GlobeNewswire)
Feb-02-23 09:54PM
Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
(GlobeNewswire)
04:01PM
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants
(GlobeNewswire)
Jan-17-23 07:00AM
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
(GlobeNewswire)
Nov-07-22 07:30AM
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
(GlobeNewswire)
07:00AM
Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million
(GlobeNewswire)
Sep-06-22 07:00AM
Avalo Advances BTLA Agonist Fusion Protein (AVTX-008) to IND-enabling Stage
(GlobeNewswire) +22.29%
Sep-01-22 07:00AM
Avalo to Present at the H.C. Wainwright Global Investment Conference
(GlobeNewswire)
Aug-11-22 04:01PM
Avalo Therapeutics Announces Board Changes
(GlobeNewswire) +6.06%
Aug-09-22 10:39AM
These 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer
(TipRanks) +32.14%
Aug-04-22 07:30AM
Avalo Reports Second Quarter 2022 Financial Results and Provides Business Updates
(GlobeNewswire) +10.96%
Aug-02-22 07:30AM
Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)
(GlobeNewswire)
Aug-01-22 07:00AM
Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
(GlobeNewswire)
Jul-06-22 04:05PM
Avalo Therapeutics Announces One-for-Twelve Reverse Stock Split
(GlobeNewswire) -20.97%
Jun-20-22 12:10PM
Investors in Avalo Therapeutics (NASDAQ:AVTX) have unfortunately lost 90% over the last three years
(Simply Wall St.)
Jun-02-22 07:30AM
Avalo to Present at the 2022 Jefferies Healthcare Conference
(GlobeNewswire)
May-18-22 07:30AM
Avalo Therapeutics Announces First Patient Dosed in the Phase 2 PEAK Trial of AVTX-002 for the Treatment of Non-Eosinophilic Asthma (NEA)
(GlobeNewswire) +6.82%
May-17-22 07:30AM
Avalo to Present at the H.C. Wainwright Global Life Sciences Conference
(GlobeNewswire) +15.08%
Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.
PresidentDr. Garry A. Neil M.D.
M.D.Dr. Mittie Doyle FACR
Chief Business OfficerMr. Taylor Boyd
Founder and Chairman of Scientific Advisory BoardDr. Solomon H. Snyder M.D.
Founder and Member of Scientific Advisory BoardDr. Barbara S. Slusher Ph.D.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Doyle MittieChief Medical OfficerJun 23 '26Option Exercise8.041,45011,65853,226Jun 25 05:24 PM
Doyle MittieChief Medical OfficerJun 23 '26Sale18.001,45026,10051,776Jun 25 05:24 PM
JONATHAN GOLDMANDirectorJun 02 '26Proposed Sale14.3942,833616,226Jun 02 04:08 PM
Doyle MittieChief Medical OfficerMay 28 '26Option Exercise8.046795,45947,801Jun 01 04:05 PM
Doyle MittieChief Medical OfficerMay 28 '26Sale16.0067910,86447,122Jun 01 04:05 PM
Doyle MittieChief Medical OfficerMay 15 '26Option Exercise12.653,00037,9506,622May 19 04:10 PM
Doyle MittieChief Medical OfficerMay 15 '26Sale18.763,00056,2803,622May 19 04:10 PM
Sullivan Christopher RyanChief Financial OfficerMay 07 '26Option Exercise9.8818,606183,82719,029May 11 04:05 PM
Sullivan Christopher RyanChief Financial OfficerMay 07 '26Sale24.1218,606448,818423May 11 04:05 PM
CHRISTOPHER SULLIVANOfficerMay 07 '26Proposed Sale21.8118,606405,797May 07 04:20 PM
VARKI PAULChief Legal OfficerMay 06 '26Option Exercise12.5375,063940,38278,697May 07 04:18 PM
VARKI PAULChief Legal OfficerMay 06 '26Sale20.1775,0631,513,6733,634May 07 04:18 PM
Sullivan Christopher RyanChief Financial OfficerMay 06 '26Option Exercise8.0447,000377,88047,423May 07 04:16 PM
Sullivan Christopher RyanChief Financial OfficerMay 06 '26Sale20.1947,000948,722423May 07 04:16 PM
Doyle MittieChief Medical OfficerMay 06 '26Option Exercise11.41106,5551,215,844110,177May 07 04:16 PM
Doyle MittieChief Medical OfficerMay 05 '26Option Exercise10.791,67918,1095,301May 07 04:16 PM
Doyle MittieChief Medical OfficerMay 06 '26Sale20.68106,5552,203,5033,622May 07 04:16 PM
Doyle MittieChief Medical OfficerMay 05 '26Sale16.001,67926,8643,622May 07 04:16 PM
Chan MitchellDirectorMay 06 '26Sale22.883,16772,4613,166May 07 04:15 PM
MITTIE DOYLEOfficerMay 06 '26Proposed Sale16.2654,508886,300May 06 04:54 PM
CHRISTOPHER SULLIVANOfficerMay 06 '26Proposed Sale16.2647,000764,220May 06 04:32 PM
PAUL VARKIOfficerMay 06 '26Proposed Sale16.2692,7711,508,456May 06 04:30 PM
MITCHELL CHANDirectorMay 06 '26Proposed Sale16.263,16751,495May 06 04:29 PM
Sullivan Christopher RyanChief Financial OfficerApr 30 '26Sale13.238,457111,853423May 01 04:37 PM
Sullivan Christopher RyanChief Financial OfficerApr 29 '26Sale13.098,458110,7368,880May 01 04:37 PM
CHRISTOPHER SULLIVANOfficerApr 29 '26Proposed Sale12.8616,915217,527Apr 29 04:33 PM
Doyle MittieChief Medical OfficerApr 06 '26Option Exercise12.653,97050,2207,592Apr 08 04:51 PM
Doyle MittieChief Medical OfficerApr 06 '26Sale18.013,97071,5083,622Apr 08 04:51 PM
MITTIE DOYLEOfficerApr 06 '26Proposed Sale17.7665,8001,168,608Apr 06 04:34 PM
Sullivan Christopher RyanChief Financial OfficerApr 02 '26Sale17.157,980136,82317,338Apr 03 03:14 PM
Sullivan Christopher RyanChief Financial OfficerApr 01 '26Sale16.777,979133,77025,318Apr 03 03:14 PM
Doyle MittieChief Medical OfficerApr 01 '26Option Exercise8.046795,4594,301Apr 03 03:13 PM
Doyle MittieChief Medical OfficerApr 01 '26Sale16.0067910,8643,622Apr 03 03:13 PM
CHRISTOPHER SULLIVANOfficerApr 01 '26Proposed Sale14.9315,959238,268Apr 01 04:48 PM
Doyle MittieChief Medical OfficerMar 16 '26Option Exercise11.5725,492294,85129,114Mar 18 04:07 PM
Doyle MittieChief Medical OfficerMar 16 '26Sale16.1525,492411,6073,622Mar 18 04:07 PM
MITTIE DOYLEOfficerMar 16 '26Proposed Sale15.8029,529466,558Mar 16 04:39 PM
Goldman JonathanDirectorNov 14 '25Option Exercise9.888,20081,0168,200Nov 17 04:05 PM
Goldman JonathanDirectorNov 14 '25Sale14.3311,367162,9370Nov 17 04:05 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 1 minute for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)